Kevin L. Keim, PhD Appointed as Chief Development Officer
27 February 2007
INC Research, a therapeutically focused contract research organisation with a trusted process for delivering reliable results, announced today the appointment of Kevin L. Keim, Ph.D., M.Sc., to the key position of chief development officer. In this role, Dr. Keim will oversee a number of the company's major initiatives, including global business development, marketing and communications, regulatory services (including safety and pharmacovigilance), early clinical-phase product development services, and the pediatrics division, building on INC Research's specialised expertise in these areas. Dr. Keim will also take the helm of INC's innovative new outreach program to the Japanese pharma and biotech business community.
"Dr. Keim will play a pivotal role in expanding INC Research's Trusted Process™ methodologies", said James T. Ogle, chief executive officer of INC Research. "His leadership abilities and clinical and operative expertise span the full spectrum of drug development activities, from strategic program development and risk-sharing strategies to late-phase and pediatric trials. Dr. Keim's energy and expertise add tremendous value for our customers."
Dr. Keim is a seasoned and classically trained pharmacologist, bringing more than 39 years of research and discovery, clinical research and regulatory experience to INC Research. He has a strong working and experiential knowledge in fundamental drug discovery and asset evaluation, all phases of clinical development, strategic and tactical operations, pharmaceutical science, and strategic regulatory science.
"INC Research has grown at an impressive pace this past year on a solid and successful business platform", Dr. Keim observed. "As an active member of the INC Research board of directors during the last five years, I have had the opportunity to support the organisation's plan for strategic growth and high-quality products in a highly competitive CRO market and have been pleased to help INC Research build itself into a well-respected, customer-centric leader in the industry. This is an exciting time to take on this new role with INC Research, and I look forward to elevating INC Research to an even larger presence in the global drug development arena."
Most recently, Dr. Keim served as president and CEO and board director of Vela Pharmaceuticals Inc., as well as founder and managing principal of K.L. Keim Consulting Group, LLC. Prior to Vela Pharmaceuticals Inc., Dr. Keim was president of Quintiles Pacific, Inc., where he provided executive leadership and directive consultative solutions in the global CNS therapeutics market. His formative years in the pharmaceutical industry were spent at Hoffmann-La Roche and Wyeth.
Dr. Keim currently sits on the boards of directors of the American Society of Experimental NeuroTherapeutics (ASENT), NeuroMedix, Inc., Clinilabs, Inc., and the Affiliated Research Institute. He received his doctoral degree from New York University and his master's of science degree from Fairleigh Dickinson University. His undergraduate work was done at Delaware Valley College, where he is now a trustee and a representative to the Bucks County PA BioTechnology Center. Dr. Keim holds membership in a variety of professional organizations.
